Medical disclaimer: This article is for educational purposes only and is not medical advice. Topical GHK-Cu may be compounded with a prescription; injectable GHK-Cu is not FDA-approved. Consult a licensed physician or dermatologist before use, especially if you have a copper metabolism disorder.
GHK-Cu is the exception in the peptide world: a compound with actual human randomized controlled trials behind it. While BPC-157 and TB-500 lean almost entirely on animal data, GHK-Cu’s skin benefits have been measured in double-blind human studies with objective instruments.
For the broader peptide landscape, see our peptide dosage chart and complete peptide guide for beginners.
What Is GHK-Cu?
GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine (GHK), first isolated in the early 1970s by chemist Loren Pickart. GHK is present in human plasma, saliva, and urine; bound to copper it becomes GHK-Cu, the biologically active form driving tissue remodeling.
Skin Rejuvenation: The Strongest Evidence
The 2015 trial (Clinical, Cosmetic and Investigational Dermatology): double-blind, 71 women with photodamaged facial skin, 12 weeks. The GHK-Cu cream group showed statistically significant improvements in fine-line depth, wrinkle severity, skin laxity on ultrasound, photoaging scores, and skin thickness; placebo showed no significant changes. The GHK-Cu cream also outperformed vitamin C and retinoic acid formulations on overall improvement.
The 2022 trial (Dermatologic Therapy, n=71, 12 weeks): the 1% GHK-Cu cream group saw a 55.7% reduction in wrinkle volume and 32.8% reduction in wrinkle depth versus control, and beat Matrixyl 3000 on collagen I stimulation (2.1-fold vs 1.4-fold).
Hair Growth: Promising but Early
GHK-Cu stimulates dermal papilla cells, promotes angiogenesis around follicles, modulates VEGF and FGF growth factors, and may extend the anagen (growth) phase. Human hair trials are small and largely industry-funded — the mechanism is sound but finasteride-level evidence does not exist.
Safety and Contraindications
- Copper metabolism disorders (Wilson’s disease, Menkes disease): absolute contraindications
- Active malignancy: theoretical concern from proangiogenic effects, unstudied
- Pregnancy: not studied; avoid
Topical use in healthy adults has the best safety data of any peptide in this series. Injectable GHK-Cu was placed on FDA Category 2 in September 2023, blocking routine compounding.
The Bottom Line
GHK-Cu earns its reputation more honestly than most peptides: real human RCTs, objective measurements, peer-reviewed publication, clinically meaningful effect sizes. The topical form has the evidence. The injectable trend does not. Follow the human data, and talk to a dermatologist before experimenting.
This article is educational content, not medical advice. For more on peptide safety, see Peptide Safety: Side Effects and What Doctors Want You to Know.
Frequently Asked Questions
Is GHK-Cu FDA-approved? Topical GHK-Cu is on the FDA’s Category 1 list (compoundable with prescription) — not the same as FDA approval. Injectable GHK-Cu is Category 2.
Can GHK-Cu regrow hair? It may support follicle health, but human hair-regrowth trials equivalent to minoxidil/finasteride studies don’t exist.
Are copper peptides safe? Topically, in people without copper metabolism disorders, trial safety data is reassuring.
Interested in Peptides?
If you’re interested in exploring peptide therapy, click here to learn more.
